Grant Award Details
- Synthesis of a Universal Endosomal Escape Domain (uEED) to optimize Anti-COVID siRNA delivery into human iPSC-derived Alveloar Epithelial Cells (AECs).
Grant Application Details
- Development of Anti-COVID RNAi Therapeutics Using Human iPSC-Derived Alveolar Epithelial Cells
To optimize a new approach to deliver Anti-COVID siRNAs into human iPSC-derived lung cells that can selectively kill the COVID virus
Our proposal, if successful, will solve the siRNA delivery problem and rapidly open the door to Anti-COVID siRNA therapeutics.
Major Proposed Activities
- Complete synthesis of a new delivery device called a Universal Endosomal Escape Domain (uEED)
- Generate a panel of human iPSC-derived lung cells
- Test and optimize the ability of the uEED to deliver Anti-COVID siRNAs into human iPSC-derived lung cells
- Rapidly expand the uEED technology to delivery of Anti-COVID siRNAs in a broader panel of human iPSC-derived lung cells
COVID-19 is a deadly health hazard for all Californians, Americans and the world. siRNA-induced RNAi responses are highly selective genetic medicines that have great potential to treat COVID patients and to prophylactically inoculate Californians to prevent their infection. However, due to a delivery problem, we cannot yet deliver siRNAs into lung cells of patients. Our proposal, if successful, will solve the siRNA delivery problem and rapidly open the door to Anti-COVID siRNA therapeutics.